ghk-cu subcutaneous ghk cu or intramuscular Peptide Thermodynamically stable ionic liquid microemulsions

It can also be used as adjuvant therapy to treat a range of medical disorders

Roxas and Viswanathan 2018)

Encourage rest, promote nutrition, administer iron therapy, and monitor for hypoxia

BPC-157 helps with chronic tendinopathy based on its mechanism of action, targeting the degenerative tissue environment that defines the condition, though direct human clinical evidence for tendinopathy specifically does not exist

If one were to extrapolate from existing human trials: Dose: 0.51 mg per day Route: Sublingual or subcutaneous Duration: Up to 20 days (as used in circadian gene studies) Yet these regimens should not be considered prescriptive or approved protocols

Rehab & Recovery TRIGGER POINT INJECTIONS What they are, how they mechanically and chemically disrupt chronic muscle knots, and what to expect from the procedure